Investor & News

Investors & News

Corporate Profile

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using the company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.

The company’s first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease.

The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company’s belief in the broad potential for its proprietary approach.

Press Releases

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

January 17, 2024

BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

January 8, 2024

– Data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome – – End of Phase 1/2a study result ...

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 4, 2024

BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...

Corporate Presentation

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.

Investor Events

January 10, 2024 at 6:45 PM EST
Investor Inquiries